Kristine A. MooreJulia T. OstrowskyAlison M. KraigsleyAngela J. MehrJoseph S. BreseeMartin H. FriedeBruce G. GellinJosephine P. GoldingPeter J. HartAnn MoenCharlotte L. WellerMichael T. OsterholmWilliam AmpofoWendy BarclayMarco CavaleriCheryl CohenBenjamin CowlingRebecca CoxIan GustBruce InnisGagandeep KangJacqueline KatzFlorian KrammerPunnee PitisuttithumDiane PostLarisa RudenkoMarilda SiqueiraJerry WeirEuropean Medicines AgencyInstitute of Experimental Medicine of the North-West Branch of the Russian Academy of Medical SciencesNational Institute for Communicable DiseasesUniversitetet i BergenUniversity of Minnesota Twin CitiesOrganisation Mondiale de la SantéUniversity of MelbourneFundacao Oswaldo CruzWellcome TrustCenters for Disease Control and PreventionUniversity of GhanaImperial College LondonIcahn School of Medicine at Mount SinaiMahidol UniversityFood and Drug AdministrationNational Institutes of Health (NIH)The University of Hong KongChristian Medical College, VellorePATH Center for Vaccine Innovation & AccessThe Sabin Vaccine InstituteCenter for Infectious Disease Research and Policy2022-08-042022-08-042021-10-29Vaccine. Vol.39, No.45 (2021), 6573-6584187325180264410X2-s2.0-85117200775https://repository.li.mahidol.ac.th/handle/20.500.14594/75994Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryReviewSCOPUS10.1016/j.vaccine.2021.08.010